Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

A Novel Method to Generate and Expand Clinical-Grade, Genetically Modified, Tumor-Infiltrating Lymphocytes

2 Aug 2017

Abstract excerpt

Following the clinical success achieved with the first generation of adoptive cell therapy (ACT) utilizing in vitro expanded tumor-infiltrating lymphocytes (TIL), the second and third generations of TIL ACT are evolving towards the use of genetically-modified TIL. TIL therapy generally involves the transfer of a high number of TIL, ranging from 109 to 1011 cells. One of the technical difficulties in genetically...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to CAR-T cell therapy research
Share to Immunotherapy and Immune Responses
Share to Virus-based gene therapy research

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Source

Identifiers

PMID: 28824634
DOI: 10.3389/fimmu.2017.00908

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 9 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

A Novel Method to Generate and Expand Clinical-Grade, Genetically Modified, Tumor-Infiltrating LymphocytesPMID 28824634Read ↗

Clinical application of genetically modified T cells in cancer therapySemantic proximity Read ↗

The transfer of genetically engineered lymphocytes in melanoma patients: a Phase I dose escalation studySemantic proximity Read ↗

Tumor-infiltrating lymphocyte therapy for melanoma: rationale and issues for further clinical development.Semantic proximity Read ↗

Generation of tumor-infiltrating lymphocyte cultures for use in adoptive transfer therapy for melanoma patients.Semantic proximity Read ↗

Peptide-MHC-targeted retroviruses enable <i>in vivo</i> expansion and gene delivery to tumor-specific T cellsSemantic proximity Read ↗

Genetically engineered T cells for the treatment of cancerSemantic proximity Read ↗

T cell receptor (TCR) gene therapy to treat melanoma: lessons from clinical and preclinical studiesSemantic proximity Read ↗

Enhanced interleukin-2 production in human tumor-infiltrating lymphocytes engineered by 3'-truncated interleukin-2 gene.Semantic proximity Read ↗

Adoptive cell transfer as personalized immunotherapy for human cancer.Semantic proximity Read ↗

Automated Manufacturing of Potent CD20-Directed Chimeric Antigen Receptor T Cells for Clinical Use.Semantic proximity Read ↗

Proliferative, phenotypic and functional and molecular characteristics of tumour-infiltrating lymphocytes obtained from unselected patients with malignant melanomas and expanded in vitro in the presence of recombinant interleukin-2.Semantic proximity Read ↗

Successful ex vivo expansion of tumor infiltrating lymphocytes with systemic chemotherapy prior to surgical resectionSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.